Table 3.
Grade 3/4 treatment-related adverse events, analyzed by type of bevacizumab-based combination
| G3/4 trAEs | Heterogeneity | df | P-value | I2 | τ2 |
|---|---|---|---|---|---|
| Bevacizumab + FOLFOX4 vs FOLFOX4 | 0.00 | 0 | NA | NA | 0.0000 |
| Bevacizumab + FU/LV vs FU/LV | 0.60 | 1 | 0.438 | 0.0% | 0.0000 |
| Bevacizumab + IFL vs IFL | 0.00 | 0 | NA | NA | 0.0000 |
| Bevacizumab + capecitabine vs capecitabine | 0.00 | 0 | NA | NA | 0.0000 |
Abbreviations: df, degrees of freedom; FOLFOX4, oxaliplatin, fluorouracil, and leucovorin; FU/LV, fluorouracil and leucovorin; G3/4 trAEs, grade 3/4 treatment-related adverse events; IFL, irinotecan, fluorouracil, and leucovorin; NA, not available.